Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Raw Materials (2021 - 2025)

Fortress Biotech has reported Raw Materials over the past 5 years, most recently at $2.8 million for Q1 2025.

  • Quarterly results put Raw Materials at $2.8 million for Q1 2025, down 32.82% from a year ago — trailing twelve months through Mar 2025 was $2.8 million (down 32.82% YoY), and the annual figure for FY2024 was $3.2 million, down 31.12%.
  • Raw Materials for Q1 2025 was $2.8 million at Fortress Biotech, down from $3.2 million in the prior quarter.
  • Over the last five years, Raw Materials for FBIO hit a ceiling of $8.4 million in Q1 2022 and a floor of $2.8 million in Q1 2025.
  • Median Raw Materials over the past 5 years was $5.1 million (2021), compared with a mean of $5.2 million.
  • Biggest five-year swings in Raw Materials: skyrocketed 46.89% in 2022 and later plummeted 34.53% in 2023.
  • Fortress Biotech's Raw Materials stood at $5.6 million in 2021, then increased by 15.83% to $6.5 million in 2022, then decreased by 28.11% to $4.6 million in 2023, then plummeted by 31.12% to $3.2 million in 2024, then dropped by 12.14% to $2.8 million in 2025.
  • The last three reported values for Raw Materials were $2.8 million (Q1 2025), $3.2 million (Q4 2024), and $3.6 million (Q3 2024) per Business Quant data.